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Abstract 
Body: 
Background: Mtb is the leading cause of death from infection. Essential 
enzymes that have not yet been targeted in Mtb include those that synthesize 
Coenzyme A (CoA) and phosphopantetheinyl transferase (PptT). PptT 
transfers phosphopantetheine from CoA to acyl carrier proteins (Acps) 
involved in synthesis of cell wall lipids, siderophores and virulence 
factors. Methods: Screening identified 8918, a mycobactericidal compound 
related to proguanil, an antimalarial. Proguanil was inactive on Mtb, while 
8918 was inactive on E. coli, S. aureus and human cells. We isolated Mtb 
clones resistant to 8918, sequenced their genomes for genes of interest, 
made knockouts, assayed recombinant proteins, solved the co-crystal 
structure of the target with 8918, and tested 8918’s effect on Mtb’s 
metabolome, lipidome and survival in mice. Results: Mutation, enzymatic 
and crystallographic evidence identified PptT (Rv2794c) as the target of 
8918. 8918 reduced Mtb’s mycolates, mycobactins and phthiocerol 
dimycocerosates and blocked growth in mice. Resistance was also conferred 
by mutations in rv2795c, encoding an enzyme of unknown function, as 
phenocopied by deletion of rv2795c. Rv2795c reversed the increase in mass 
that accompanied phosphopantetheinylation of an Acp. Conclusions: PptT 
can be inhibited to a degree that kills Mtb. The mycobactericidal effect of 
8918 depends on the action of a new enzyme, hypothesized to be a 
phosphopantetheinyl hydrolase (PptH) that counteracts PptT. Loss of function 
in an enzyme that antagonizes the function of the drug target is a new 
mechanism of antimicrobial resistance. 
 
  
Platform Research Presentation – Wednesday, September 6, 2017 4:45 pm – 5:30 pm 
 
Session Title: 
 
AMR, Regulatory Science, and Drug Development 
 
 
Presentation 
Title: 
 
Inhibitors of Nucleotidyltransferase Superfamily Enzymes asa Novel 
Antibacterial Agent 
Author 
Block: 
F. Cao1, M. Donlin2, C. Orth1, M. Meyers3, R. Murelli4, P. Adegboyega1, J. 
Tavis3; 1St. Louis VA Hlth.care System, St. Louis, MO, 2St Louis Univ., St. 
Louis, MO, 3St. Louis Univ., St. Louis, MO, 4City Univ. of New York, New 
York, NY 
 
Abstract 
Body: 
Background: Novel antibiotics are urgently needed. The 
nucleotidyltransferase superfamily (NTS) includes many nucleic acid-
processing enzymes. We hypothesized that bacteria would be sensitive to 
NTS inhibitors. 
Methods: We screened for growth inhibition against E. coli, Staphylococcus 
saprophyticus, S. aureus, Acinetobacter baumannii, Pseudomonas 
aeruginosa and patient-derived multi-drug resistant (MDR) bacteria. 
Preliminary hits were assessed for minimum inhibitory concentrations (MIC80) 
and cytotoxicity (CC50) against human hepatoma cells. The top 5 compounds 
were selected for MIC80 evaluation against MDR bacteria. Results: 254 NTS 
compounds were screened. For gram-positive bacteria, compounds #43 
(cicloprox-like), #53, 54 (tropolone), #51, 62, 63, 282, 283, 285 (benzoylated 
tropolones), #46, 262 (α-hydroxytropolones) and #140 (Elvitagravir 
derivative) inhibited ≥80% growth of S. aureus (methicillin-sensitive, MSSA) 
and/or S. saprophyticus at <20 µM with CC50 >50 µM. Compounds #63 and 
285 inhibited 22 methicillin-resistant Staphylococcus aureus (MRSA) strains 
with similar MIC80 values as against MSSA strains. For gram-negative rods, 
#284 and 363 inhibited E. coli and MDR-E.coli, as well as other MDR-
enterobacteriaceae, with MIC80 ≤30 µM. #261 inhibited MDR A. 
baumanni with MIC80 ≤ 30 µM and CC50 >50 µM. The MDR bacteria have 
variable drug resistant mechanisms. This indicates these inhibitors, and 
probably similar analogs, act against novel antibacterial 
target(s). Conclusions: NTS inhibitors from multiple chemotypes have 
antibacterial activity and they inhibit bacterial replication by a mechanism 
distinct from existing antibiotics. 
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Abstract 
Body: 
Background: Hydrophilic antibiotics preferentially use non-specific porins, 
channel-forming proteins in the outer membrane of Gram-negative bacteria, 
to gain access to the cell interior. Two major porin-based mechanisms for 
antibiotic resistance have been reported: alterations of the porin expression 
or altered function due to specific mutations reducing permeability. 
In Escherichia coli, OmpF is considered a major pathway for the 
translocation of ß-lactam antibiotics and newer generations of quinolone 
antibiotics. The X-ray structure of OmpF reveals a homotrimer, with each 
monomer forming a separate ß-barrel composed of sixteen ß-strands 
spanning the outer membrane (Fig. 1A and 1B). A key feature in the 
structure of OmpF is the presence of a constriction region due to loop L3, 
which folds back into the channel, forming both a steric and electrostatic 
hindrance (Fig. 1C). This zone is characterized by a strong transversal 
electric field, generated by the negatively charged residues D113 and E117 
on the L3 side facing a cluster of positively charged arginines (R42, R82, and 
R132). Methods: In this work, we investigated the impact of porin structure 
on antibiotic permeability by using complementary in vivo approaches. 
Specifically, we characterized translocation of ß-lactam antibiotics across the 
OmpF and OmpC orthologs from four Gram-negative “superbugs”. Results: - 
E. coli OmpF and OmpC are good models to study the permeation of β-
lactam antibiotics; - Low permeation of compounds across OmpC is mainly 
due to charge and size penalties; - Our investigation using resazurin-based 
viability assays in porinless E. coli has proven to be a fast and reliable 
method to study the permeation of unlabeled antibiotics across individual 
porin. Conclusions: Improved understanding of porin specificity, the nature 
of porin-antibiotic interactions, and the structure-kinetics of porin 
translocation would facilitate the design of new antibiotics that can reach high 
intracellular concentration. 
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Abstract 
Body: 
Background: Eravacycline (ERV) (7-fluoro-9-pyrrolidinoacetamido-6-
demethyl-6-deoxytetracycline or TP-434) is a novel, fully-synthetic 
fluorocycline of the tetracycline class that is designed to retain activity against 
the two main acquired tetracycline-specific resistance mechanisms: drug 
efflux pumps and ribosomal protection. ERV is particularly active against 
several life-threatening multidrug-resistant pathogens that are rapidly 
emerging worldwide, including Acinetobacter baumannii and carbapenem-
resistant Enterobacteriaceae. We characterized the plasma pharmacokinetics 
and tissue distribution of ERV in rabbits after multiple dosing in order to 
establish a AUC/MIC relationship to tissue concentrations and to bridge that 
relationship to human dosing as a foundation for potential investigation in 
treatment of experimental bacterial infections. Methods: ERV was 
administered to NZW rabbits at 0.5, 1, 2, and 4 mg/kg IV QD with a 5-10 min 
infusion (n = 20 (4/dosage group)) for 6 days. Plasma PK and tissue 
concentrations were analyzed at the end of the study. Infusion time was 10 
min for all rabbits. 
Results: 
     Dose 
(mg/kg) 
AUC(o-24) 
(hr∙ng/mL) 
Cmax 
(ng/mL) 
CL 
(L/hr/kg) 
Vss 
(L/kg) 
0.5 2,529 ± 338 997 ± 27.7 0.20 ± 0.03 1.39 ± 0.14 
1 5,787 ± 854 2,035 ± 462 0.18 ± 0.03 1.19 ± 0.07 
2 10,871 ± 428 4,102 ± 283 0.18 ± 0.01 1.10 ± 0.02 
4 29,888 ± 1,868 8,695 ± 1,537 0.12 ± 0.01 1.64 ± 0.21 
 
Assuming an MIC of 1 µg/mL, for any one of MDR Enterobacteriaciae, these 
data indicates that fAUC/MIC ratios at 1 or 2 mg/kg Q12 IV of 3.3. to 6.7 
would predict potent activity in plasma and in most tissue sites. Highest 
concentrations of ERV were achieved in kidney, spleen, and liver. 
Proportional levels of ERV were achieved in all 25 studied tissue/fluid 
sites. Conclusion: The plasma pharmacokinetic profile of 0.5 to 4 mg/kg of 
in NZW rabbits yields comparable exposure to that of humans and provides a 
platform for further study of eravacycline against MDR bacterial pathogens. 
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Abstract 
Body: 
Background: With the increase in drug-resistant pathogens associated with 
urinary tract infections (UTI), a focus of drug development is to optimally 
define the drug exposure that prevents the emergence of drug-resistant 
pathogens for investigational agents. Gepotidacin is a novel 
triazaacenaphthylene bacterial type II topoisomerase inhibitor in development 
for the treatment of patients with uncomplicated UTI. Studies using an in 
vitro HFIM were conducted to determine the magnitude of gepotidacin 
AUC:MIC ratio required to prevent the amplification of drug-
resistant Escherichia coli subpopulations. This study was supported by GSK 
and funded through OTA HHSO100201300011C with 
HHS/BARDA. Methods: The challenge isolate, E. coli ATCC 13441 (MIC = 2 
mg/L), was studied using an inoculum of 108 CFU/mL. Free-drug plasma 
concentration-time human profiles for gepotidacin PO doses administered to 
healthy volunteers that provided free-drug AUC0-24 values ranging from 9.7 to 
811 mg•h/L were simulated and compared to no-treatment and active 
(meropenem 1 g q8h) controls. Bacterial density was determined by 
evaluating bacterial populations on drug-free and antibiotic-containing agar 
plates at 2.5 and 4 x MIC over 10 days. The subset of isolates that grew on 
drug-containing agar plates was collected for MIC determination, with and 
without the presence of 40 mg/L of the broad-spectrum pump inhibitor, phe-
arg-beta-napthalymide dihydrochloride. Results: An inverted-U shaped 
function described the relationship between drug-resistance amplification and 
free-drug AUC:MIC ratio for data from both sets of gepotidacin-containing 
agar plates. MIC values of the isolates collected from the drug-containing 
plates ranged from 8 to 32 mg/L. MIC values returned to the baseline value 
when examined in the presence of the broad-spectrum efflux pump inhibitor. 
Over the 10-day study period, a free-drug AUC:MIC ratio ≥ 275 prevented E. 
coli resistance amplification in the HFIM model. Conclusions: These data 
can be used to support the selection of gepotidacin dosing regimens for the 
treatment of patients with uncomplicated UTI arising from E. coli that 
minimize the potential for on-therapy drug-resistance amplification. 
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Abstract 
Body: 
New therapeutic strategies are needed to address the growing challenge of 
antimicrobial resistance in multidrug-resistant (MDR) Gram-negative 
bacterial pathogens. Synthetic peptidomimetic compounds have high 
therapeutic potential as they are typically stable in vivo, being less subject to 
proteolytic degradation compared to traditional peptides. Here we employed 
a screening approach to identify peptidomimetic compounds that in 
combination induce susceptibility of Gram-negative pathogens to 
antimicrobials that are primarily used against Gram-positive pathogens. 
Forty-six synthetic peptidomimetic compounds were screened for synergy 
with azithromycin or rifampicin in clinical isolates of MDR Escherichia 
coli sequence type 131 (ST131), MDR Klebsiella pneumoniae ST258 
and Pseudomonas aeruginosa. Exposure to three peptidomimetics at 0.5 µM 
inhibited growth of at least two strains/species in combination with 
antimicrobial concentrations approximating the clinical breakpoint for Gram-
positive species. These three peptidomimetics were further screened with a 
panel of 22 drugs representing 10 clinically-used antimicrobial classes. 
However, the concomitant presence of each of these peptidomimetics at ≤1 
µM did not reduce the minimal inhibitory concentrations (MIC) below clinical 
susceptible breakpoints for antimicrobials other than azithromycin and 
rifampicin. For all three MDR strains, antimicrobial synergy was confirmed by 
checkerboard assays with fractional inhibitory concentration indices (FICIs) 
ranging from 0.01 to 0.28 for all three peptidomimetics in combination with 
rifampicin, and from 0.04 to 0.28 for two peptidomimetics in combination with 
azithromycin. The third peptidomimetic-azithromycin combination had FICIs 
ranging from 0.25 to 0.37 in E. coli. All synergistic combinations reduced the 
antibiotic MICs below the clinical resistance breakpoints. Overall, this study 
identified three peptidomimetics that overcome intrinsic resistance to 
azithromycin and rifampicin in Gram-negative pathogens, making them in 
vitro susceptible to antibiotic concentrations that are achieved by standard 
dosage in clinical practice. The identified synergistic combinations will be 
further investigated to determine their cytotoxicity, strain variability and in 
vivo efficacy. 
 
